Pembrolizumab-Associated acute tubular interstitial nephritis with asymptomatic serum creatinine elevation: A case report
Scientific Reports in Medicine · 26.04.2026 · 3 (1) · 57-63
DOI: 10.37609/srinmed.65 ↗Kurz gefasst
Fallbericht in der Zeitschrift Scientific Reports in Medicine, online erschienen am 26.04.2026. Verfasst von Mehmet Mutlu Kidi und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICPIs) have transformed cancer treatment but may cause immune-related adverse events (irAEs) affecting multiple organ systems. Renal irAEs, particularly tubulointerstitial nephritis (TIN), are uncommon yet clinically significant, and their optimal diagnosis and management — including the decision to rechallenge — remain areas of active investigation. A 59-year-old male with metastatic lung adenocarcinoma and high PD-L1 expression (TPS 80%) received pembrolizumab monotherapy. After eight cycles, asymptomatic acute kidney injury (AKI; serum creatinine 2.97 mg/dL) was detected during routine monitoring. Clinical and laboratory evaluation — including peripheral eosinophilia and pyuria with leukocyte casts on urine microscopy — supported a diagnosis of TIN without recourse to kidney biopsy. The Naranjo Adverse Drug Reaction Probability Scale score was 8, indicating a probable association with pembrolizumab. Prednisolone was initiated, and serum creatinine returned to baseline within 5 days. Following complete renal recovery and a joint oncology–nephrology risk–benefit assessment, pembrolizumab was successfully rechallenged. The patient completed 12 additional cycles with stable renal function and no recurrence of AKI. This case demonstrates that pembrolizumab-associated TIN may present as entirely asymptomatic creatinine elevation, underscoring the importance of routine biochemical monitoring. A biopsy-free diagnostic approach was feasible when clinical and laboratory findings were concordant. The successful rechallenge outcome contributes to the limited evidence supporting individualized ICPI resumption following grade 3 renal irAEs.
Zitieren
APA
Kidi, M. M., Bayram, E., Kaya, B., Köşeci, T., Kara, İ. O., & Şahin, B. (2026). Pembrolizumab-Associated acute tubular interstitial nephritis with asymptomatic serum creatinine elevation: A case report. Scientific Reports in Medicine, 3(1), 57-63. https://doi.org/10.37609/srinmed.65
Vancouver
Kidi MM, Bayram E, Kaya B, Köşeci T, Kara İO, Şahin B. Pembrolizumab-Associated acute tubular interstitial nephritis with asymptomatic serum creatinine elevation: A case report. Scientific Reports in Medicine. 2026;3(1):57-63. doi:10.37609/srinmed.65
BibTeX
@article{Kidi2026,
author = {Kidi, Mehmet Mutlu and Bayram, Ertugrul and Kaya, Bülent and Köşeci, Tolga and Kara, İsmail Oğuz and Şahin, Berksoy},
title = {Pembrolizumab-Associated acute tubular interstitial nephritis with asymptomatic serum creatinine elevation: A case report},
journal = {Scientific Reports in Medicine},
year = {2026},
volume = {3},
number = {1},
pages = {57--63},
doi = {10.37609/srinmed.65}
}
EUVIMED